MabCure, Inc. (OTC:MBCI) announced that it has signed a research agreement with AZ Sint Lucas Hospital in Brugge, Belgium. The hospital intends to conduct a preclinical research to broaden the utility of MabCure’s monoclonal antibodies to diagnose cancer in tissue samples. All results will be in the property of MabCure.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Formerly Smartec Holdings, Mabcure Inc is focused on the development and commercializing of products to detect cancer at an early stage. The company’s products are also used to create antibodies and novel drugs to combat cancer. MBCI established MabCure, N.V., a wholly owned subsidiary, on October 30, 2008.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
